Info

VINNAPAS® UW 1 FS

From parquet adhesives to automotive body parts – a wide range of applications contain solid resins.

Close

WACKER BIOSOLUTIONS

At WACKER BIOSOLUTIONS, sales of €205.9 million (2016: €206.4 million) were on par with the prior-year level. The quantities sold rose, but sales were dampened by slightly lower prices and negative exchange-rate effects. WACKER BIOSOLUTIONS generated its highest sales growth at its Pharma/Agro business line. Sales declined slightly at its Food unit. Due to project business, the sales trend varied across individual regions, with sales rising in the Americas and Germany.

was €37.5 million (2016: €37.0 million), slightly above the prior-year level. The EBITDA margin was 18.2 percent (2016: 17.9 percent).

Capital expenditures increased year over year, to €15.7 million (2016: €9.1 million). Investment spending focused on two major projects. One priority was to modernize and expand the large-scale fermentation plant that we had acquired in Spain in 2016. Our aim is to concentrate our manufacturing operations at that plant and to make bioengineered products for other customers there. In our pharmaceutical proteins business, we invested in various modernization measures at our site in Jena (Germany). Employee numbers totaled 533 as of December 31, 2017 (2016: 510).

 (XLS:) Download XLS
Key Data: WACKER BIOSOLUTIONS

 

  

 

  

 

€ million

  

20171

  

20161

  

2015

  

2014

  

2013

 

  

 

  

 

  

 

  

 

  

 

1

Costs from selling expenses reclassified to R&D expenses as of 2016

 

  

 

  

 

  

 

  

 

  

 

Total sales

  

205.9

  

206.4

  

197.1

  

176.2

  

158.4

EBITDA

  

37.5

  

37.0

  

32.2

  

23.6

  

23.6

EBITDA margin (%)

  

18.2

  

17.9

  

16.3

  

13.4

  

14.9

EBIT

  

26.1

  

25.7

  

21.0

  

13.6

  

17.2

Capital expenditures

  

15.7

  

9.1

  

6.2

  

8.4

  

10.2

R&D expenses

  

6.0

  

6.2

  

6.1

  

6.7

  

7.0

Employees (December 31, number)

  

533

  

510

  

491

  

484

  

371

 

  

 

  

 

  

 

  

 

  

 
EBITDA
Earnings before interest, taxes, depreciation and amortization.
Cysteine
Cysteine is a sulfur-containing amino acid. It belongs to the non-essential amino acids, as it can be formed in the body. It is used, for example, as an additive in foods and cough mixtures. Cysteine and its derivatives are a business field at WACKER BIOSOLUTIONS.